These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 16120063

  • 1. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 2. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 5. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Dec; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 7. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [Abstract] [Full Text] [Related]

  • 8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE, Nicholls AJ, Kamm BR.
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [Abstract] [Full Text] [Related]

  • 10. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 11. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 12. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [Abstract] [Full Text] [Related]

  • 13. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 15. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP, Vathsala A, Lou HX, Zhou S, Chan E.
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication.
    Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM.
    Ther Drug Monit; 2002 Oct; 24(5):598-606. PubMed ID: 12352931
    [Abstract] [Full Text] [Related]

  • 17. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.
    Clin Pharmacokinet; 2009 Aug; 48(5):329-41. PubMed ID: 19566116
    [Abstract] [Full Text] [Related]

  • 19. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P, Albert C, Busque S, St-Louis G, Vinet B.
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [Abstract] [Full Text] [Related]

  • 20. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
    Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J.
    Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.